<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365794</url>
  </required_header>
  <id_info>
    <org_study_id>GCRC Protocol 1156</org_study_id>
    <nct_id>NCT00365794</nct_id>
  </id_info>
  <brief_title>Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men</brief_title>
  <official_title>Investigator Initiated Study of the Effects of Androgen Therapy on Carbohydrate and Lipid Metabolism In Elderly Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A. HYPOTHESES: In older men low testosterone levels, abdominal obesity and elevated fasting
      insulin who are at risk for the cardiovascular complications such as heart attack and stroke.

        1. Supplemental testosterone will decrease abdominal adipose tissue and hepatic fat) and
           appendicular fat and intramyocellular lipid in peripheral muscles (IMCL).

        2. Supplemental testosterone will improve insulin sensitivity by:

             1. Decreasing hepatic glucose output (HGO), a measure of central insulin resistance

             2. increasing peipheral glucose disposal (Rd), a measure of periperal insuln
                sensiivity

             3. . Improving peripheral glucose disposal (Rd) by reducing IMCL

             4. Increasing appendicular skeletal muscle mass

      B. OBJECTIVES:

        1. Primary Objective: To determine the effects of supplemental testosterone to achieve
           testosterone levels in the upper normal physiologic range on central adipose tissue
           (abdominal and hepatic fat) and peripheral skeletal muscle fat (appendicular fat and
           IMCL).

        2. Secondary Objectives: To determine the effects of supplemental testosterone to achieve
           testosterone levels in the upper normal physiologic range:on central insulin sensitivity
           ( hepatic glucose output ([HGO]) and peripheral insulin sensitivity (glucose disposal
           (Rd)

      Results of this study will provide greater understanding whether androgen therapy enhances
      insulin sensitivity by decreasing HGO, improving peripheral Rd and if these desired effects
      are achieved, whether they are due to reductions in abdominal fat or liver lipid, IMCL or
      effects of augmenting muscle mass per se.

      Results will generate hypotheses to investigate cellular and molecular mechanisms of androgen
      effects in persons at risk for the Metabolic Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is an investigator-initiated open label, study to investigate the effects
      of supplemental testosterone (gel formulation) to increase testosterone levels to the upper
      normal range in 12 older hypogonadal (testosterone levels less than 300 ng/dL) men with
      abdominal obesity and elevated fasting insulin levels. Subjects will be assigned to receive
      10 g of transdermal testosterone (Androgel) every morning to achieve levels in the upper
      normal physiologic range (similar to men in the 3rd and 4th decades) for 20 weeks.

        -  For the primary objective, regional adipose tissue, namely DEXA measures of abdominal
           and appendicular fat mass and hepatic fat, and IMCL will be quantified by
           1H-spectroscopy at baseline (study week 0) and at study week 20 (completion of study
           therapy).

        -  For the secondary objective, insulin sensitivity (peripheral Rd, hepatic glucose output
           [HGO]) and hepatic gluconeogenesis will be measured directly during a two stage
           hyperinsulinemic euglycemic clamp at baseline and study week 20.

        -  Indirect markers of lipid (adiponectin, ApoB 100) and carbohydrate metabolism (Fasting
           blood sugar, HOMA-IR) at study week 10, and study week 20.

      All components of the study will be conducted in the USC NIH-funded (NCRR), General Clinical
      Research Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking. This was an open label (un-blinded)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Mass and Regional Adipose Adiposiy</measure>
    <time_frame>Baseline to 20 weeks</time_frame>
    <description>Change in total body mass, total fat mass, trunk fat, and extremity fat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hepatic Lipid</measure>
    <time_frame>Baseline to week 20</time_frame>
    <description>Amount of liver fat is highly predictive of insulin resistance. Hepatic fat is measured by MR spectroscopy and adjusted for H2O and results are reported as ratio of these two.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intramyocellular Lipid (IMCL)</measure>
    <time_frame>Baseline to week 20</time_frame>
    <description>IMCL is quantified by MR spectroscopy of the anterior tibialis muscle of the leg. The value is adjusted for creatine and reported as a ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Total Body Fat</measure>
    <time_frame>Baseline and 20 weeks</time_frame>
    <description>Percentage of total body fat is quantified by DEXA scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total and Regional Carbohydrate Metabolism During a 2-hr Hyperinsulinemic Euglycemic Clamp and [6,6-2H2] Glucose Studies (Peripheral Glucose Disposal [Rd],Hepatic Glucose Output [HGO])</measure>
    <time_frame>Baseline and 20 weeks</time_frame>
    <description>In the final analysis, total and regional carbohydrate metabolism during a 2-hr hyperinsulinemic euglycemic clamp (peripheral glucose disposal [Rd],hepatic glucose output [HGO]) were analyzed by mass transfer of glucose during both stages of the clamp relative to insulin levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Skeletal Muscle Mass by DEXA</measure>
    <time_frame>Baselne to 20 weeks</time_frame>
    <description>Skeletal muscle mass was assesed by regional DEXA to quantify appendicular lean tissues which is primarily muscle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Lipids</measure>
    <time_frame>Baseline to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Baseline to week 20</time_frame>
    <description>HOMA-IR is a measure of insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Basal FFAs in Plasma</measure>
    <time_frame>Baseline to week 20</time_frame>
    <description>FFA (plasma free fatty acids) are measure of lipid metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Free Fatty Acids During Glucose Clamp</measure>
    <time_frame>Baseline to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Aging</condition>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label treatment without masking with each participant serving as his own control. Measurements are compared before and after treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical testosterone gel 10 g/day</intervention_name>
    <description>Testosterone gel therapy for 20 weeks</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Entry Criteria:

          -  Men &gt; 60 years of age

          -  Total testosterone &lt; 300 ng/dL

          -  Waist circumference &gt;102 cm

          -  Fasting insulin level &gt; 18 U/L

        Exclusion Criteria:

          -  PSA &gt; 4.1, symptoms of obstructive uropathy (AUA score &gt; 14), unexplained prostate
             nodule or gland firmness

          -  Hematocrit &gt; 50%

          -  Malignancy other than cutaneous cancers

          -  Sleep apnea requiring CPAP

          -  History of myocardial infarction, angina or stroke within the previous 6 months

          -  Clinical diagnosis of diabetes or FPG &gt; 126 mg/dL

          -  Hypothyroidism not controlled to euthyroid levels with medication for at least 3
             months

          -  LDL-C &gt;160 mg/dL

          -  Transaminases &gt; 1.5X ULN

          -  Systemic anticoagulation with warfarin

          -  Active progressive resistance training

          -  Dieting for weight loss

          -  Active inflammatory condition (e.g. rheumatoid arthritis)

          -  Use of any anabolic agent (e.g. growth hormone, testosterone precursor, anabolic
             steroid)or cytokine therapy in the proceeding 12 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred R Sattler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LAC-USC Medical Center GCRC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sattler F, He J, Chukwuneke J, Kim H, Stewart Y, Colletti P, Yarasheski K, Buchanan T. Testosterone Supplementation Improves Carbohydrate and Lipid Metabolism in Some Older Men with Abdominal Obesity. J Gerontol Geriatr Res. 2014 Jun 7;3(3):1000159.</citation>
    <PMID>25392748</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 16, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2006</study_first_posted>
  <results_first_submitted>March 22, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2019</results_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Fred Sattler, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Older men</keyword>
  <keyword>Abdominal obesity</keyword>
  <keyword>Central obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Low testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential subjects were primarily recruited from 2011 to 2013 and were evaluated and studied at the University of Southern California CTSI Clinical Trials Unit. 22 subjects met all eligibility requirements and begun study therapy with testosterone gel. Two did not complete treatment. Thus, 20 completed all evaluations as planned.</recruitment_details>
      <pre_assignment_details>Consenting subjects were evaluated for eligibility and had to be:
Men 60 years-or-older, with morning testosterone &lt;400ng/dL, waist circumference ≥102cm, and evidence of insulin resistance; HgbA1c of 5.7-6.4% [20] or HOMA-IR ≥4.0. Exclusion criteria included diabetes, PSA ≥4.0μg/L, hct ≥50%, AST ≥2X ULN, concurrent inflammatory condition.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Arm</title>
          <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22">22 subjects were enrolled since only 20 completed all post treatment measures.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>open label treatment with testosterone gel</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" lower_limit="62.0" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AM total testosterone level</title>
          <units>nmoles/liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.6" lower_limit="5.2" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>waist circumference</title>
          <units>centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114" lower_limit="104" upper_limit="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>blood panels</title>
          <units>mmole/liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.61" lower_limit="3.00" upper_limit="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.11" lower_limit="0.98" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.06" lower_limit="0.62" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.59" lower_limit="0.72" upper_limit="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient history at enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Family history of diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking ever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking currently</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On Rx for lipid disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On Rx for hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body compotion</title>
          <description>kilograms as measured by DEXA</description>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Total body mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.5" lower_limit="84.4" upper_limit="133.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" lower_limit="24.3" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.3" lower_limit="13.6" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremity fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.9" lower_limit="9.1" upper_limit="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total lean body mss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" lower_limit="47.1" upper_limit="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremity lean mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" lower_limit="21.2" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of body fat</title>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" lower_limit="23.9" upper_limit="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin senstivity</title>
          <units>dL/min per μU/mL;</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Whole body insulin sensivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.93" lower_limit="1.07" upper_limit="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic glucose output</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.89" lower_limit="0.03" upper_limit="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rate of glucose disposal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.93" lower_limit="1.07" upper_limit="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA-IR</title>
          <units>microU/L) x fasting glucose (nmol/L)/22.</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.55" lower_limit="0.64" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Basal free fatty acids</title>
          <units>mEq/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.35" lower_limit="0.24" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Change in glucose clamp free fatty acids over 0 to 4 hours</title>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.30" lower_limit="0.17" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatic lipid</title>
          <description>Measurement is adjusted for water content and commonly reported as ratio</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.11" lower_limit="0.01" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intramyocellular lipid (IMCL)</title>
          <description>IMCL is commonly adjusted for creatine (Cr) content and reported as a raio</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" lower_limit="0.2" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Mass and Regional Adipose Adiposiy</title>
        <description>Change in total body mass, total fat mass, trunk fat, and extremity fat</description>
        <time_frame>Baseline to 20 weeks</time_frame>
        <population>Data for one participant was not available</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Mass and Regional Adipose Adiposiy</title>
          <description>Change in total body mass, total fat mass, trunk fat, and extremity fat</description>
          <population>Data for one participant was not available</population>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total body mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-4.8" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-7.4" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-4.6" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremity fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-3.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Total body mass</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Total fat mass</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis is for change in trunk fat mass after 20 weeks of testosterone gel.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis is for change in extremity fat mass after 20 weeks of testosterone gel.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hepatic Lipid</title>
        <description>Amount of liver fat is highly predictive of insulin resistance. Hepatic fat is measured by MR spectroscopy and adjusted for H2O and results are reported as ratio of these two.</description>
        <time_frame>Baseline to week 20</time_frame>
        <population>Data not available for one subject</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment without masking with each participant serving as his own control. Measurements are compared before and after treatment.
Topical testosterone gel 10 g/day: Testosterone gel therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepatic Lipid</title>
          <description>Amount of liver fat is highly predictive of insulin resistance. Hepatic fat is measured by MR spectroscopy and adjusted for H2O and results are reported as ratio of these two.</description>
          <population>Data not available for one subject</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36" lower_limit="-84" upper_limit="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>No adjustment in p for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intramyocellular Lipid (IMCL)</title>
        <description>IMCL is quantified by MR spectroscopy of the anterior tibialis muscle of the leg. The value is adjusted for creatine and reported as a ratio</description>
        <time_frame>Baseline to week 20</time_frame>
        <population>data not available for 5 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Intramyocellular Lipid (IMCL)</title>
          <description>IMCL is quantified by MR spectroscopy of the anterior tibialis muscle of the leg. The value is adjusted for creatine and reported as a ratio</description>
          <population>data not available for 5 subjects</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30" lower_limit="-85" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Total Body Fat</title>
        <description>Percentage of total body fat is quantified by DEXA scanning</description>
        <time_frame>Baseline and 20 weeks</time_frame>
        <population>Data not available for one subject</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Total Body Fat</title>
          <description>Percentage of total body fat is quantified by DEXA scanning</description>
          <population>Data not available for one subject</population>
          <units>percentage of total body fat</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-6.5" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>No adjustment for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total and Regional Carbohydrate Metabolism During a 2-hr Hyperinsulinemic Euglycemic Clamp and [6,6-2H2] Glucose Studies (Peripheral Glucose Disposal [Rd],Hepatic Glucose Output [HGO])</title>
        <description>In the final analysis, total and regional carbohydrate metabolism during a 2-hr hyperinsulinemic euglycemic clamp (peripheral glucose disposal [Rd],hepatic glucose output [HGO]) were analyzed by mass transfer of glucose during both stages of the clamp relative to insulin levels.</description>
        <time_frame>Baseline and 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total and Regional Carbohydrate Metabolism During a 2-hr Hyperinsulinemic Euglycemic Clamp and [6,6-2H2] Glucose Studies (Peripheral Glucose Disposal [Rd],Hepatic Glucose Output [HGO])</title>
          <description>In the final analysis, total and regional carbohydrate metabolism during a 2-hr hyperinsulinemic euglycemic clamp (peripheral glucose disposal [Rd],hepatic glucose output [HGO]) were analyzed by mass transfer of glucose during both stages of the clamp relative to insulin levels.</description>
          <units>dL/min per μU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Whole body insulin sensitiity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="-2.44" upper_limit="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hepaic glucose output (HGO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" lower_limit="-2.58" upper_limit="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>peripheral glucose disposal (Rd)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="-3.08" upper_limit="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for change in whole body insulin sensitivity after treatment with testosterone gel for 20 weeks.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for change in hepatic glucose output (measure of central insulin sensitivity) after treatment with testosterone gel for 20 weeks</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for change in rate of peripheral glucose disposal (test of peripheral insulin sensitivity) after treatment with testosterone gel for 20 weeks</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Skeletal Muscle Mass by DEXA</title>
        <description>Skeletal muscle mass was assesed by regional DEXA to quantify appendicular lean tissues which is primarily muscle.</description>
        <time_frame>Baselne to 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Skeletal Muscle Mass by DEXA</title>
          <description>Skeletal muscle mass was assesed by regional DEXA to quantify appendicular lean tissues which is primarily muscle.</description>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-1.1" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in DEXA extremity (appendicular) lean tissue, a measure of extremity muscle mass after 20 weeks ot treatent with testosterone gel.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Lipids</title>
        <time_frame>Baseline to week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Lipids</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-2.70" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" lower_limit="-1.74" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" lower_limit="-1.45" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-0.60" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A change in 20 plasma lipids (fasting triglycerides and lipid fractions) after 20 weeks of treatment with testosterone gel.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test for fasting triglycerides</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A change in 20 plasma lipids (fasting triglycerides and lipid fractions) after 20 weeks of treatment with testosterone gel</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test for total cholesterol</non_inferiority_desc>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>nts A change in 20 plasma lipids (fasting triglycerides and lipid fractions) after 20 weeks of treatment with testosterone gel</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test for LDL cholesterol</non_inferiority_desc>
            <p_value>.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A change in 20 plasma lipids (fasting triglycerides and lipid fractions) after 20 weeks of treatment with testosterone gel</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test for HDL cholesterol</non_inferiority_desc>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HOMA-IR</title>
        <description>HOMA-IR is a measure of insulin resistance</description>
        <time_frame>Baseline to week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HOMA-IR</title>
          <description>HOMA-IR is a measure of insulin resistance</description>
          <units>microU/L) x fasting glucose (nmol/L)/22</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" lower_limit="-6.94" upper_limit="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Basal FFAs in Plasma</title>
        <description>FFA (plasma free fatty acids) are measure of lipid metabolism</description>
        <time_frame>Baseline to week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Basal FFAs in Plasma</title>
          <description>FFA (plasma free fatty acids) are measure of lipid metabolism</description>
          <units>mEq/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.22" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Free Fatty Acids During Glucose Clamp</title>
        <time_frame>Baseline to 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Open label treatment with each participant serving as his own control. Data is compared before and after treatment.
Topical testosterone (Androgel) 10 g/day: Testosterone therapy for 20 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Free Fatty Acids During Glucose Clamp</title>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.12" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks for each participant</time_frame>
      <desc>No serious adverse events occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>Open Label Testosterone Treatment</title>
          <description>No serious adverse events occurred
PSA and Framingham CV Disease Risk Score did not increase</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ACTG</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary limitation of this small pilot study is that it does not have a control group.
It is also likely under-powered and thus unable to show significance differences for some measurements.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Fred Sattler, MD</name_or_title>
      <organization>University of Southern California</organization>
      <phone>323-409-4635</phone>
      <email>fsattler@usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

